Travere Therapeutics (TVTX) Current Leases (2020 - 2026)
Travere Therapeutics posted quarterly Current Leases of $6.0 million for Q1 2026, up 10.2% year-on-year from $5.5 million in Q1 2025, and up 2.42% on a QoQ basis from $5.9 million in Q4 2025.
Travere Therapeutics (TVTX) has 7 years of Current Leases data on file, last reported at $6.0 million in Q1 2026.
- For the quarter ending Q1 2026, Current Leases rose 10.2% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (up 10.2% YoY), and the FY2025 full-year result was $5.9 million, up 8.7% from the prior year.
- Current Leases for Q1 2026 stood at $6.0 million, up from $5.9 million in the prior quarter.
- Across five years, Current Leases topped out at $6.0 million in Q1 2026 and bottomed at $4.0 million in Q1 2022.
- The 5-year median for Current Leases is $5.0 million (2024), against an average of $5.0 million.
- The widest annual swing landed in 2022, when Current Leases rose 13.43%; it then increased 8.25% in 2025.
- A 5-year view of Current Leases shows it stood at $4.4 million in 2022, then gained by 10.74% to $4.9 million in 2023, then increased by 10.1% to $5.4 million in 2024, then increased by 8.7% to $5.9 million in 2025, then increased by 2.42% to $6.0 million in 2026.
- The last three Current Leases figures came in at $6.0 million (Q1 2026), $5.9 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.02 Mn |
| Dec 31, 2025 | 5.88 Mn |
| Sep 30, 2025 | 5.73 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Mar 31, 2025 | 5.46 Mn |
| Dec 31, 2024 | 5.41 Mn |
| Sep 30, 2024 | 5.30 Mn |
| Jun 30, 2024 | 5.16 Mn |
| Mar 31, 2024 | 5.04 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Sep 30, 2023 | 4.78 Mn |
| Jun 30, 2023 | 4.66 Mn |
| Mar 31, 2023 | 4.55 Mn |
| Dec 31, 2022 | 4.43 Mn |
| Sep 30, 2022 | 4.23 Mn |
| Jun 30, 2022 | 4.12 Mn |
| Mar 31, 2022 | 4.01 Mn |
| Dec 31, 2021 | 3.91 Mn |
| Dec 31, 2020 | 357,000.00 |